Vaborbactam

Multidrug-resistant bacterial infection is a severe clinical challenge in the global anti-infection field at present. As a new generation of β-lactamase inhibitor, veborbactam irreversibly binds to class A, class C and part of class D β-lactamases, effectively solving the problem of bacterial resistance to traditional β-lactam antibiotics. It is often clinically used in combination with antibiotics such as piperacillin and ceftazidime, mainly for the treatment of complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired pneumonia and ventilator-associated pneumonia. It is applicable to adult and pediatric patients over 12 years old with drug-resistant bacterial infection, providing a new treatment option for multidrug-resistant Gram-negative bacterial infection.

At present, the global market size of veborbactam-related preparations has exceeded 1.2 billion US dollars, with a compound annual growth rate of more than 18% in the past three years. The growth momentum mainly comes from the upgraded clinical demand for treatment regimens for drug-resistant bacterial infections. The domestic market is still in the early stage of development, with fewer than 5 enterprises having obtained approval for generic preparations. With the continuous rise in the detection rate of drug-resistant bacteria, the domestic market growth rate is expected to reach 25% in the next five years, and no obvious market concentration pattern of leading enterprises has emerged yet.

The original research enterprise of veborbactam is Entasis Therapeutics, and the original brand name is Xacduro, which is a compound preparation of sulbactam and veborbactam. The core compound patent of this product expires in China in 2038. The original marketed dosage form is injection, with a specification of 1g sulbactam and 1g veborbactam per vial. At present, the original compound preparation has been included in the FDA Reference Listed Drug Catalog, and its import has not been approved in China yet. As of now, 2 domestic enterprises have submitted CDE registration applications for veborbactam API, all with the status of "A", and another 3 enterprises have veborbactam compound preparations in the marketing declaration stage. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of veborbactam impurity reference standards, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the regulatory requirements of the Chinese Pharmacopoeia, FDA and other regulations, and can provide stable reference standard support for pharmaceutical enterprises in the whole process of API R&D, quality research and preparation declaration.